Keywords: HIV Vaccine; prime-boost; SHIV model; protein vaccine; DNA vaccine; HIV-1/MuLV model
The project covers preclinical evaluation of an improvement of an adjuvant protein HIV vaccine that entered clinical evaluation in February 2002. The improvement will be achieved through a combination of the adjuvanted protein vaccine with particle-mediated immune delivery of DNA (PMID-DNA) in a prime-boost immunisation regimen. This regimen will be investigated in mice and rhesus monkeys for superior immunogenicity and for efficacy in HAART.
The projects work contributes to developing an efficacious HIV-1 vaccine. The rationale of the immunisation strategy is targeted at preventing disease and eventually showing therapeutic benefit to already diseased individuals. Both vaccines’ profiles would be of value to public health.
The primary aim is to improve an adjuvanted protein clade B HIV vaccine. The secondary aim is to demonstrate, in mice and monkeys, the increase of HIV-specific humoral and cellular immune responses induced by a prime-boost regimen over single modality administration, ie. adjuvanted protein vaccine alone. The efficacy of a prime-boost regimen will be demonstrated in MuLV-mice and SHIV monkey models.
The benefit of a prime-boost approach over a single modality approach demonstrated in preclinical immunogenicity and efficacy studies. Identification of an optimal immunisation schedule.
Clinical evaluation of the prime-boost approach combining adjuvanted protein vaccine and PMID-DNA, both in prophylactic and therapeutic setting.
Rue de l’Institut 89
Tel: +32 2 656 8243
Fax: +32 2 656 9009
|Official Address||Other Information|
|2||Britta Wahren||Swedish Institute for Infectious Disease Control and Microbiology and Tumorbiology Centre |
|Tel: +46 8 457 2300 |
Fax: +46 8 337 272
|3||Jonathan Heeney||Foundation Biomedical Primate Research Centre (BPRC), Department of Virology |
Lange Kleiweg 139
NL-2280 GJ Rijswijk
|Tel: +31 15 284 2660 |
Fax: +31 15 284 3986